Publicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (27)

2024

  1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  2. Standardization of the definition of the types of oncological colectomy. Delphi method for consensus of experts of the Spanish Association of Surgeons

    Cirugia Espanola, Vol. 102, Núm. 9, pp. 484-494

  3. Surgery for inflammatory bowel disease in Spain: How are we doing? Initial results of a nationwide prospective registry

    Cirugia Espanola, Vol. 102, Núm. 7, pp. 355-363

  4. Ultrasound Cut-Off Values for Rectus Femoris for Detecting Sarcopenia in Patients with Nutritional Risk

    Nutrients, Vol. 16, Núm. 11

2023

  1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  2. Safety and feasibility of transradial access for percutaneous coronary intervention in chronic total occlusions

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 253-260

  3. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  4. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    ESMO Open, Vol. 7, Núm. 3

  5. The EPICTER score: a bedside and easy tool to predict mortality at 6 months in acute heart failure

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2348-2356

  6. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Epidemiology and prognosis of patients with a history of cancer admitted to intensive care. A multicenter observational study

    Medicina Intensiva, Vol. 45, Núm. 6, pp. 332-346

  2. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  3. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  4. Institutional factors associated with adherence to enhanced recovery protocols for colorectal surgery: Secondary analysis of a multicenter study

    Journal of Clinical Anesthesia, Vol. 74

  5. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

  6. Medication‐related osteonecrosis of the jaw: A critical narrative review

    Journal of Clinical Medicine, Vol. 10, Núm. 19

2020

  1. Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: Secondary analysis of POWER trial

    Minerva Anestesiologica, Vol. 87, Núm. 1, pp. 13-25